Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4 ...

Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment First ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

Sleeve gastrectomy and Roux-en-Y gastric bypass for people with obesity and liver cirrhosis was associated with longer ...

The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.

Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - - First presentation of topline ...

Crinetics Pharma's Paltusotine shows strong Phase 3 results for acromegaly. Click here to find out why CRNX stock is a Buy.